Company / Shareholders' Equity
Jade Biosciences, Inc. Shareholders' Equity History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$76.4M
FY2024
5-year range
-$13.3M / $172.4M
FY2020-FY2024
Trend
-30.2%
vs FY2023
Sector context
#174 of 214
Health Care
What the data says
Jade Biosciences, Inc.'s shareholders' equity of $76M is lower than 81% of companies in the Health Care sector (FY2024). Shareholders' Equity has declined for 3 consecutive years, from $172M in FY2021 to $76M in FY2024.
Based on SEC 10-K filings.
$76M in FY2024 with a 3-year CAGR of -23.8%.
Declined from $127M to $76M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -23.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 214This company $76.4M Sector average $2.6B
▼
-97.0% below sector average
Key checks
Key Insights
- Jade Biosciences, Inc.'s shareholders' equity has declined for 3 consecutive years.
- 3-year CAGR of -23.8%, indicating a declining trend.
- In FY2024, shareholders' equity decreased 30.2% year-over-year.
- Ranks #174 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $76.4M | -30.2% |
| FY2023 | $109.5M | -13.6% |
| FY2022 | $126.7M | -26.5% |
| FY2021 | $172.4M | +1392.1% |
| FY2020 | -$13.3M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026